Showing papers by "Michael A. Heneghan published in 2006"
TL;DR: JAK2V617F occurs in a high proportion of patients with Budd-Chiari Syndrome and is of use in the characterization of latent MPD in BCS, and was missed in a substantial number of subjects by using standard techniques.
265 citations
TL;DR: The findings suggest that AIH often presents in older patients, who frequently have severe disease, and active management in these patients can lead to a normal life expectancy.
173 citations
TL;DR: It is confirmed that favorable outcomes of pregnancy post‐ LT can be expected for the majority of patients, however, delaying pregnancy until after 1‐year post‐LT is advisable, since doing so may be associated with a lower risk of prematurity.
149 citations
TL;DR: In conclusion, a complex relationship exists between HLA and PBC, and some genetic associations may be population specific.
125 citations
TL;DR: Data indicate that diabetic status is one of the more important variables determining the severity of HCV recurrence and is synergistic with donor age, which may provide an additional management opportunity to modify the impact of HCv recurrence.
117 citations
TL;DR: A > 10-fold cost differential exists between the charges associated with more potent immunosuppression and standard therapy, and it behoves clinicians not only to consider end point pertaining to efficacy, but also end points pertaining to cost-effectiveness in evaluating novel immunosppression in autoimmune hepatitis.
Abstract: In > 80% of patients with autoimmune hepatitis, steroid therapy alone or in combination with azathioprine results in disease remission. Treatment response results in reversal of fibrosis and excellent long-term survival in many patients, whereas untreated patients may expect a 10-year survival of 10-fold cost differential exists between the charges associated with more potent immunosuppression and standard therapy. Therefore, in evaluating novel immunosuppression in autoimmune hepatitis, it behoves clinicians not only to consider end points pertaining to efficacy, but also end points pertaining to cost-effectiveness. Moreover, the exact role of pharmacogenomics and genotyping of thiopurine methyltransferase in patients with autoimmune hepatitis needs to be fully defined.
27 citations
TL;DR: It is concluded that change in MELD score whilst on the transplant waiting list has a significant effect on survival post‐transplant although MELD Score at the time of transplant appears to have the most significant impact on resource utilization.
Abstract: Allocation of donor livers through the model for end-stage liver disease (MELD) score has resulted in a fall in waiting list deaths in the United States. Change in MELD score (DeltaMELD) whilst awaiting transplant has been suggested as a method of refining organ allocation. Our aims were to analyse the effect of DeltaMELD between listing and transplant, and examine its impact on patient survival, intensive care stay and hospital stay in 402 patients transplanted for chronic liver disease at a single centre. Patients who had a DeltaMELD score of >+1 point were more likely to die in hospital following transplant (P < 0.05) and had a significantly worse 12- and 36-month survival post transplant (P < 0.0001) when compared with patients with DeltaMELD
11 citations